Department of Pathology, Massachusetts General Hospital, Boston, USA.
Department of Pathology, Harvard Medical School, Boston, MA, USA.
Mod Pathol. 2022 May;35(5):615-624. doi: 10.1038/s41379-021-00974-9. Epub 2021 Dec 8.
Lymphocyte-activation gene 3 (LAG-3) modulates the tumor microenvironment through immunosuppressive effects. Its associations with clinicopathologic parameters and prognostic significance in non-small-cell lung carcinomas remain unclear. We examined LAG-3 expression in 368 resected non-small-cell lung carcinomas (including 218 adenocarcinomas and 150 squamous-cell carcinomas) using tissue microarrays, with normalization to CD8 T-cell count (LAG-3/CD8 index), and correlated LAG-3, CD8, and LAG-3/CD8 index with clinicopathologic features, molecular status, and survival. LAG-3 expression in the immune cells (ranged 0.35-540.1 cells/mm²) was identified in 92% of non-small-cell lung carcinomas. In adenocarcinomas and squamous-cell carcinomas, LAG-3 expression correlated with CD8 T-cell count and PD-L1 expression. In adenocarcinomas, high LAG-3 expression (defined as >median) was additionally associated with smoking history, high T stage, aggressive pathologic features (solid-predominant histologic pattern, lymphovascular invasion, and nodal metastasis), and lack of EGFR mutation. In the entire resected tumor cohort and in adenocarcinomas, high LAG-3 and LAG-3/CD8 index were each associated with worse overall survival. In squamous-cell carcinomas, high CD8 was associated with better overall survival. In an exploratory analysis of pretreatment samples from advanced non-small-cell lung carcinoma patients treated with pembrolizumab, high CD8 was predictive of improved overall and progression-free survival, while high LAG-3, but not high LAG-3/CD8 index, was associated with improved progression-free survival. In conclusion, the clinicopathologic correlations and prognostic impact of LAG-3 in non-small-cell lung carcinoma are histotype-dependent, highlighting differences in the immune microenvironment between adenocarcinomas and squamous-cell carcinomas. The predictive impact of LAG-3 warrants further investigation.
淋巴细胞激活基因 3(LAG-3)通过免疫抑制作用调节肿瘤微环境。其与非小细胞肺癌的临床病理参数的关联及其预后意义尚不清楚。我们使用组织微阵列检查了 368 例切除的非小细胞肺癌(包括 218 例腺癌和 150 例鳞状细胞癌)中 LAG-3 的表达,并用 CD8 T 细胞计数(LAG-3/CD8 指数)进行了归一化,并将 LAG-3、CD8 和 LAG-3/CD8 指数与临床病理特征、分子状态和生存相关联。在 92%的非小细胞肺癌中,免疫细胞中的 LAG-3 表达(范围为 0.35-540.1 个细胞/mm²)被鉴定出来。在腺癌和鳞状细胞癌中,LAG-3 表达与 CD8 T 细胞计数和 PD-L1 表达相关。在腺癌中,高 LAG-3 表达(定义为>中位数)还与吸烟史、高 T 期、侵袭性病理特征(实性为主的组织学模式、血管淋巴管侵犯和淋巴结转移)以及缺乏 EGFR 突变有关。在整个切除肿瘤队列中和腺癌中,高 LAG-3 和 LAG-3/CD8 指数均与总体生存率较差相关。在鳞状细胞癌中,高 CD8 与总体生存率较好相关。在接受 pembrolizumab 治疗的晚期非小细胞肺癌患者的预处理样本的探索性分析中,高 CD8 与总生存期和无进展生存期的改善相关,而高 LAG-3(但不是高 LAG-3/CD8 指数)与无进展生存期的改善相关。总之,LAG-3 在非小细胞肺癌中的临床病理相关性和预后影响与组织类型有关,突出了腺癌和鳞状细胞癌之间免疫微环境的差异。LAG-3 的预测作用值得进一步研究。